NextCure, Inc. Common Stock (NXTC) Stock Price

NXTCStock

$6.09+18.71%52W

Market Cap$27.88M

P/E—

PEG Ratio—

Div yield—

Beta1.37

NXTC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-64.57%

Price vs S&P 500 (4W)36.87%

VGM Score66.21

Book Value / Share (Quarterly)$7.41

P/TBV (Annual)0.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-13.85

Price vs S&P 500 (YTD)-69.90%

Net Profit Margin (TTM)-65.22%

EPS (TTM)$-18.75

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-18.75

EPS (Annual)$-2.00

ROI (Annual)-85.53%

Net Profit Margin (5Y Avg)-825.97%

Cash / Share (Quarterly)$8.24

ROA (Last FY)-69.26%

EBITD / Share (TTM)$-15.23

ROE (5Y Avg)-45.43%

Operating Margin (TTM)-82.06%

Cash Flow / Share (Annual)$-14.15

P/B Ratio1.43x

P/B Ratio (Quarterly)1.42x

Net Income / Employee (Annual)$-1,400,000

EV / Revenue (TTM)0.84x

ROA (TTM)-124.62%

EPS Incl Extra (Annual)$-2.00

Current Ratio (Annual)4.14x

Quick Ratio (Quarterly)4.32x

3-Month Avg Trading Volume1.53M

52-Week Price Return18.71%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.54

P/S Ratio (Annual)1.70x

Asset Turnover (Annual)0.07x

52-Week High$15.74

Operating Margin (5Y Avg)-865.37%

EPS Excl Extra (Annual)$-2.00

CapEx CAGR (5Y)-32.45%

Tangible BV CAGR (5Y)60.79%

26-Week Price Return-52.64%

Quick Ratio (Annual)3.96x

13-Week Price Return-4.84%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.61x

Enterprise Value$22.92M

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-1.30%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-163.54%

Cash / Share (Annual)$11.93

3-Month Return Std Dev435.67%

Net Income / Employee (TTM)$-1,366,600

ROE (Last FY)-85.53%

EPS Basic Excl Extra (Annual)$-2.00

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-18.75

ROI (TTM)-186.96%

P/S Ratio (TTM)1.39x

Pretax Margin (5Y Avg)-825.97%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.03

Price vs S&P 500 (52W)0.15%

Year-to-Date Return-57.08%

5-Day Price Return3.40%

EPS Normalized (Annual)$-2.00

ROA (5Y Avg)-39.88%

Net Profit Margin (Annual)-163.54%

Month-to-Date Return46.92%

Cash Flow / Share (TTM)$-2.22

EBITD / Share (Annual)$-2.04

Operating Margin (Annual)-184.23%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-45.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-18.75

P/TBV (Quarterly)0.28x

P/B Ratio (Annual)1.42x

Pretax Margin (TTM)-65.22%

Book Value / Share (Annual)$9.97

Price vs S&P 500 (13W)-6.80%

Beta1.37x

P/FCF (Annual)7.72x

Revenue / Share (TTM)$0.00

ROE (TTM)-186.96%

52-Week Low$1.55

vGradeA

mGradeC

vgmGradeB

NXTC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.92	-$1.85	+3.85%(+$0.07)
Q1 2026	May 7, 2026	-$2.03	-$1.87	+7.88%(+$0.16)
Q4 2025	Mar 5, 2026	-$2.29	-$0.81	+64.63%(+$1.48)
Q3 2025	Nov 5, 2025	-$3.98	-$3.22	+19.16%(+$0.76)
Q2 2025	Aug 7, 2025	-$4.62	-$11.29	-144.64%(-$6.67)

NXTC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

4.13

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
NXTCNextCure, Inc. Common Stock	A	—	C	$6.09
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About NextCure, Inc. Common Stock

NextCure is a clinical-stage biopharmaceutical company developing immunomedicines to restore immune function in cancer and immune-related diseases. Its lead candidate, NC410, a LAIR-2 fusion protein, demonstrated early clinical activity in colorectal and ovarian cancers in combination with pembrolizumab, while LNCB74, an antibody-drug conjugate targeting B7-H4, is also in clinical development. The company is seeking strategic partners for additional clinical programs including NC525 and NC318, as well as preclinical candidates in chronic bone diseases and neurological indications.